Clozaril
Product Images NDC 64725-1260

4 FDA label images from Tya Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Clozaril (NDC 64725-1260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tya Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (64725 1260)

Label Image (64725 1260)
Label for Clozaril (clozapine) 25 mg tablets with a count of 30. The label states the product is prescription only, manufactured by Novartis, and repackaged by TYA Pharmaceuticals in Tallahassee, FL. It includes placeholder lot and expiration information, a barcode, and a note to see the package insert for dosage instructions.*
FDA Label Image

Clozapine Structural Formula (Clozaril 02)

Clozapine Structural Formula (Clozaril 02)
Chemical structure diagram of Clozaril showing its molecular formula C18H18ClN4 and molecular weight 326.83. The diagram includes chlorine, nitrogen, carbon, hydrogen, and methyl groups arranged in a multi-ring system.*
FDA Label Image

Figure 2: Kaplan Meier Estimates Of Cumulative Probability Of A Significant Suicide Attempt Or Hospitalization To Prevent Suicide. (Clozaril 03)

Figure 2: Kaplan Meier Estimates Of Cumulative Probability Of A Significant Suicide Attempt Or Hospitalization To Prevent Suicide. (Clozaril 03)
A cumulative probability line graph comparing Clozapine and Olanzapine over 24 months. The x-axis represents time in months, and the y-axis shows cumulative probability. The graph indicates 24% for Clozapine and 32% for Olanzapine at the 24-month mark.*
FDA Label Image

Figure 1: Resuming Monitoring Frequency After Interruption In Therapy (Clozaril 04)

Figure 1: Resuming Monitoring Frequency After Interruption In Therapy (Clozaril 04)
Flowchart illustrating blood monitoring treatment duration criteria based on white blood cell (WBC) count and absolute neutrophil count (ANC) levels for Clozaril treatment. It categorizes treatment durations as less than 6 months, 6 to 12 months, and greater than 12 months, with branching based on the presence or absence of abnormal blood events and guidance on monitoring frequency and rechallenge instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.